TV003 Dengue Vaccine and Previous Zika Infection Against ZIKV Challenge

Phase 1, randomised, single-blind trial of Butantan-DV in Zika virus infection (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Incidence, magnitude, and duration of infectious ZIKV-SJRP/2016-184 recovered from serum following administration of ZIKV-SJRP/2016-184 in subjects who received TV003, Incidence, magnitude, and duration of infectious ZIKV-SJRP/2016-184 recovered from serum following administration of ZIKV-SJRP/2016-184 in ZIKV-exposed subjects and 4 more. Started Sep 2024; status: completed.